New hope for rare, aggressive cancers: trial tests Immune-Boosting drug
NCT ID NCT06893783
Summary
This study is testing a new drug called tarlatamab for people with a rare and aggressive type of cancer called extrapulmonary neuroendocrine carcinoma (EPNEC). The cancer has returned or worsened after standard chemotherapy. The trial will see if tarlatamab, which works by directing the body's own immune cells to attack the cancer, can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMAS (NEC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Samsung Medical Center
NOT_YET_RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
-
Yonsei Severance Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.